UK launch for Novo’s new diabetes pill
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
Read Moreby Selina McKee | Sep 1, 2020 | News | 0
Rybelsus is the world’s first and only oral GLP-1 receptor agonist
Read Moreby Selina McKee | May 27, 2020 | News | 0
The Defeat Diabetes includes a number of initiatives to provide access to affordable care to vulnerable patients and accelerate prevention to halt the rise of the disease
Read Moreby Selina McKee | Sep 4, 2018 | News | 0
Novo Nordisk and the University of Oxford are poised to begin ground-breaking work on therapeutic targets for type II diabetes with new research facilities set to open next week.
Read Moreby Selina McKee | Jun 29, 2018 | News | 0
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Read Moreby Selina McKee | Jan 8, 2018 | News | 0
Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.
Read Moreby Selina McKee | Dec 6, 2017 | News | 0
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
Read Moreby Selina McKee | Dec 6, 2016 | News | 0
Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
